{
    "info": {
        "nct_id": "NCT03807765",
        "official_title": "Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases",
        "inclusion_criteria": "* Provides signed and dated informed consent\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Age 18 or older\n* Breast cancer with brain metastases, as documented by extracranial tumor biopsy with MRI brain imaging or intracranial surgical pathology revealing brain metastases\n* 10 or less brain metastases eligible for SRS to brain metastases or to the post-operative bed\n* Maximum diameter of the largest intact brain metastases ≤ 4 cm\n* Eastern Cooperative Oncology Group performance status 0 to 2\n* Prior treatment with taxane based chemotherapy with anthracyclines (if appropriate)\n* A formalin-fixed, paraffin-embedded tumor tissue block or 10 unstained slides of intracranial/extracranial tumor sample (archival or recent) for biomarker evaluation should be made available and submitted to the central lab for correlative studies. If attempts to obtain archival tissue are unsuccessful the patient may be enrolled.\n* Individuals with prior SRS/fractioned stereotactic radiotherapy (FSRT) treatment will be allowed if active measurable disease has not previously been treated with radiation therapy\n* Continuing concurrent use of hormonal therapy or HER2-targeted therapy is allowed if the patient exhibits brain metastases progression during treatment\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the administration of each dose of study agent.\n* WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s), plus 5 half-lives of study drug (half-life up to 25 days), plus 30 days (duration of ovulatory cycle) for a total of 5 months after treatment completion.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Presence of leptomeningeal disease\n* Prior whole brain radiation therapy\n* All toxicities attributed to prior anticancer therapy must have been resolved to Grade 1 (NCI CTCAE Version 5) or baseline before administration of study drug(s) . Some exceptions apply.\n* Women who are pregnant or breastfeeding\n* Active, known, or suspected autoimmune disease. Patients with an autoimmune paraneoplastic syndrome requiring concurrent immunosuppressive treatment are excluded. Some exceptions apply.\n* Prior therapy with antiPD-1, antiPD-L1, antiPD-L2, antiCD137, or antiCTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)\n* Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity\n* Any patient requiring supplemental oxygen therapy\n* Patients with prior history of non-breast cancer malignancies are excluded except in the case of adequately treated basal cell cancer, squamous cell skin cancer, chronic lymphocytic leukemia, or other indolent diseases not requiring therapy\n* Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or that would interfere with the interpretation of safety results\n* Major surgery or significant traumatic injury that has not been recovered from by 14 days before the initiation of study drug\n* Current or prior participation in a study of an investigational agent or investigational device within 2 weeks of first dose of study treatment\n* Positive test for: a. Hepatitis B virus using Hepatitis B virus surface antigen (Hepatitis B virus surface antigen) test b. Hepatitis C virus (HCV) using HCV ribonucleic acid or HCV antibody test that indicates acute or chronic infection c. Exception: Individuals with a positive test for HCV antibody but no detection of HCV ribonucleic acid indicating no current infection are eligible\n* Medical history of testing positive for HIV or AIDS. No HIV testing is required, unless mandated by a local health authority.\n* Inadequate hematologic function\n* Inadequate hepatic function\n* Inadequate pancreatic function\n* History of allergy or hypersensitivity to any of the study drugs or study drug components\n* Individuals who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Breast cancer with brain metastases, as documented by extracranial tumor biopsy with MRI brain imaging or intracranial surgical pathology revealing brain metastases",
            "criterions": [
                {
                    "exact_snippets": "Breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as documented by extracranial tumor biopsy",
                    "criterion": "extracranial tumor biopsy documentation",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "MRI brain imaging ... revealing brain metastases",
                    "criterion": "MRI brain imaging",
                    "requirements": [
                        {
                            "requirement_type": "detection of brain metastases",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intracranial surgical pathology revealing brain metastases",
                    "criterion": "intracranial surgical pathology",
                    "requirements": [
                        {
                            "requirement_type": "detection of brain metastases",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group performance status 0 to 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group performance status 0 to 2",
                    "criterion": "Eastern Cooperative Oncology Group (ECOG) performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Maximum diameter of the largest intact brain metastases ≤ 4 cm",
            "criterions": [
                {
                    "exact_snippets": "Maximum diameter of the largest intact brain metastases ≤ 4 cm",
                    "criterion": "largest intact brain metastasis maximum diameter",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Individuals with prior SRS/fractioned stereotactic radiotherapy (FSRT) treatment will be allowed if active measurable disease has not previously been treated with radiation therapy",
            "criterions": [
                {
                    "exact_snippets": "prior SRS/fractioned stereotactic radiotherapy (FSRT) treatment will be allowed",
                    "criterion": "prior SRS/FSRT treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active measurable disease has not previously been treated with radiation therapy",
                    "criterion": "active measurable disease prior radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment with radiation therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s), plus 5 half-lives of study drug (half-life up to 25 days), plus 30 days (duration of ovulatory cycle) for a total of 5 months after treatment completion.",
            "criterions": [
                {
                    "exact_snippets": "WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s), plus 5 half-lives of study drug (half-life up to 25 days), plus 30 days (duration of ovulatory cycle) for a total of 5 months after treatment completion.",
                    "criterion": "willingness to use contraception",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "adherence to contraception instructions",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A formalin-fixed, paraffin-embedded tumor tissue block or 10 unstained slides of intracranial/extracranial tumor sample (archival or recent) for biomarker evaluation should be made available and submitted to the central lab for correlative studies. If attempts to obtain archival tissue are unsuccessful the patient may be enrolled.",
            "criterions": [
                {
                    "exact_snippets": "A formalin-fixed, paraffin-embedded tumor tissue block or 10 unstained slides of intracranial/extracranial tumor sample (archival or recent) ... should be made available and submitted to the central lab for correlative studies.",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "formalin-fixed, paraffin-embedded tumor tissue block",
                                "10 unstained slides of intracranial/extracranial tumor sample"
                            ]
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "intracranial tumor",
                                "extracranial tumor"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "archival",
                                "recent"
                            ]
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "submission",
                            "expected_value": "to the central lab for correlative studies"
                        }
                    ]
                },
                {
                    "exact_snippets": "If attempts to obtain archival tissue are unsuccessful the patient may be enrolled.",
                    "criterion": "archival tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "enrollment eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the administration of each dose of study agent.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP)",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive status",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum or urine pregnancy test",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin",
                    "criterion": "pregnancy test sensitivity",
                    "requirements": [
                        {
                            "requirement_type": "sensitivity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "IU/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 24 hours prior to the administration of each dose of study agent",
                    "criterion": "timing of pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "time before dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stated willingness to comply with all study procedures and availability for the duration of the study",
            "criterions": [
                {
                    "exact_snippets": "Stated willingness to comply with all study procedures",
                    "criterion": "willingness to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "availability for the duration of the study",
                    "criterion": "availability for the duration of the study",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with taxane based chemotherapy with anthracyclines (if appropriate)",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with taxane based chemotherapy",
                    "criterion": "taxane based chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with anthracyclines (if appropriate)",
                    "criterion": "anthracyclines chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": "if appropriate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 10 or less brain metastases eligible for SRS to brain metastases or to the post-operative bed",
            "criterions": [
                {
                    "exact_snippets": "10 or less brain metastases",
                    "criterion": "number of brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "metastases"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "eligible for SRS to brain metastases or to the post-operative bed",
                    "criterion": "eligibility for SRS to brain metastases or to the post-operative bed",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provides signed and dated informed consent",
            "criterions": [
                {
                    "exact_snippets": "Provides signed and dated informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age 18 or older",
            "criterions": [
                {
                    "exact_snippets": "Age 18 or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Continuing concurrent use of hormonal therapy or HER2-targeted therapy is allowed if the patient exhibits brain metastases progression during treatment",
            "criterions": [
                {
                    "exact_snippets": "Continuing concurrent use of hormonal therapy or HER2-targeted therapy is allowed if the patient exhibits brain metastases progression during treatment",
                    "criterion": "brain metastases progression during treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Inadequate hepatic function",
            "criterions": [
                {
                    "exact_snippets": "Inadequate hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or prior participation in a study of an investigational agent or investigational device within 2 weeks of first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Current or prior participation in a study of an investigational agent or investigational device within 2 weeks of first dose of study treatment",
                    "criterion": "participation in a study of an investigational agent or investigational device",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "temporal_relation_to_study_treatment",
                            "expected_value": "within 2 weeks of first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive test for: a. Hepatitis B virus using Hepatitis B virus surface antigen (Hepatitis B virus surface antigen) test b. Hepatitis C virus (HCV) using HCV ribonucleic acid or HCV antibody test that indicates acute or chronic infection c. Exception: Individuals with a positive test for HCV antibody but no detection of HCV ribonucleic acid indicating no current infection are eligible",
            "criterions": [
                {
                    "exact_snippets": "Positive test for: a. Hepatitis B virus using Hepatitis B virus surface antigen (Hepatitis B virus surface antigen) test",
                    "criterion": "Hepatitis B virus infection",
                    "requirements": [
                        {
                            "requirement_type": "test_result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "test_type",
                            "expected_value": "Hepatitis B virus surface antigen"
                        }
                    ]
                },
                {
                    "exact_snippets": "Positive test for: ... b. Hepatitis C virus (HCV) using HCV ribonucleic acid or HCV antibody test that indicates acute or chronic infection",
                    "criterion": "Hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "test_result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "test_type",
                            "expected_value": [
                                "HCV ribonucleic acid",
                                "HCV antibody"
                            ]
                        },
                        {
                            "requirement_type": "infection_status",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Exception: Individuals with a positive test for HCV antibody but no detection of HCV ribonucleic acid indicating no current infection are eligible",
                    "criterion": "current Hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "HCV antibody test_result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "HCV ribonucleic acid test_result",
                            "expected_value": "not detected"
                        },
                        {
                            "requirement_type": "infection_status",
                            "expected_value": "no current infection"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery or significant traumatic injury that has not been recovered from by 14 days before the initiation of study drug",
            "criterions": [
                {
                    "exact_snippets": "Major surgery ... has not been recovered from by 14 days before the initiation of study drug",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "recovery_time_before_study_drug",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant traumatic injury ... has not been recovered from by 14 days before the initiation of study drug",
                    "criterion": "significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "recovery_time_before_study_drug",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inadequate pancreatic function",
            "criterions": [
                {
                    "exact_snippets": "Inadequate pancreatic function",
                    "criterion": "pancreatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of leptomeningeal disease",
            "criterions": [
                {
                    "exact_snippets": "Presence of leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All toxicities attributed to prior anticancer therapy must have been resolved to Grade 1 (NCI CTCAE Version 5) or baseline before administration of study drug(s) . Some exceptions apply.",
            "criterions": [
                {
                    "exact_snippets": "All toxicities attributed to prior anticancer therapy must have been resolved to Grade 1 (NCI CTCAE Version 5) or baseline before administration of study drug(s)",
                    "criterion": "toxicities attributed to prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Grade 1 (NCI CTCAE Version 5)",
                                "baseline"
                            ]
                        },
                        {
                            "requirement_type": "resolution_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with prior history of non-breast cancer malignancies are excluded except in the case of adequately treated basal cell cancer, squamous cell skin cancer, chronic lymphocytic leukemia, or other indolent diseases not requiring therapy",
            "criterions": [
                {
                    "exact_snippets": "prior history of non-breast cancer malignancies are excluded",
                    "criterion": "prior history of non-breast cancer malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "except in the case of adequately treated basal cell cancer",
                    "criterion": "prior history of adequately treated basal cell cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except in the case of adequately treated ... squamous cell skin cancer",
                    "criterion": "prior history of adequately treated squamous cell skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except in the case of ... chronic lymphocytic leukemia",
                    "criterion": "prior history of chronic lymphocytic leukemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except in the case of ... other indolent diseases not requiring therapy",
                    "criterion": "prior history of other indolent diseases not requiring therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active, known, or suspected autoimmune disease. Patients with an autoimmune paraneoplastic syndrome requiring concurrent immunosuppressive treatment are excluded. Some exceptions apply.",
            "criterions": [
                {
                    "exact_snippets": "Active, known, or suspected autoimmune disease.",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune paraneoplastic syndrome requiring concurrent immunosuppressive treatment",
                    "criterion": "autoimmune paraneoplastic syndrome requiring concurrent immunosuppressive treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or that would interfere with the interpretation of safety results",
            "criterions": [
                {
                    "exact_snippets": "Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "risk_increase_with_study_participation_or_drug_administration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known medical condition that, in the investigator's opinion, ... would interfere with the interpretation of safety results",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "interference_with_safety_results_interpretation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior therapy with antiPD-1, antiPD-L1, antiPD-L2, antiCD137, or antiCTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy with antiPD-1, antiPD-L1, antiPD-L2, antiCD137, or antiCTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)",
                    "criterion": "prior therapy with immune checkpoint inhibitors or T-cell co-stimulation targeting agents",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug classes",
                            "expected_value": [
                                "antiPD-1",
                                "antiPD-L1",
                                "antiPD-L2",
                                "antiCD137",
                                "antiCTLA-4",
                                "ipilimumab",
                                "any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inadequate hematologic function",
            "criterions": [
                {
                    "exact_snippets": "Inadequate hematologic function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior whole brain radiation therapy",
            "criterions": [
                {
                    "exact_snippets": "Prior whole brain radiation therapy",
                    "criterion": "whole brain radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity",
            "criterions": [
                {
                    "exact_snippets": "Interstitial lung disease that is symptomatic",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Interstitial lung disease that ... may interfere with the detection or management of suspected drug-related pulmonary toxicity",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with detection or management of suspected drug-related pulmonary toxicity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women who are ... breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allergy or hypersensitivity to any of the study drugs or study drug components",
            "criterions": [
                {
                    "exact_snippets": "History of allergy or hypersensitivity to any of the study drugs or study drug components",
                    "criterion": "allergy or hypersensitivity to study drugs or study drug components",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Individuals who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness",
            "criterions": [
                {
                    "exact_snippets": "compulsorily detained for treatment",
                    "criterion": "compulsory detention for treatment",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric ... illness",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "physical (eg, infectious disease) illness",
                    "criterion": "physical illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Medical history of testing positive for HIV or AIDS. No HIV testing is required, unless mandated by a local health authority.",
            "criterions": [
                {
                    "exact_snippets": "Medical history of testing positive for HIV or AIDS",
                    "criterion": "HIV or AIDS status",
                    "requirements": [
                        {
                            "requirement_type": "history of positive test",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any patient requiring supplemental oxygen therapy",
            "criterions": [
                {
                    "exact_snippets": "Any patient requiring supplemental oxygen therapy",
                    "criterion": "supplemental oxygen therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}